Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04714372CT.gov FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lispro-Ph20 Component Rhuph20 (this asset) | Masonic Cancer Center, University of Minnesota | P1 | CC · 44 |
| Fludarabine | M.D. Anderson Cancer Center | P2/3 | BBB |
| Cyclophosphamide | Actinium Pharmaceuticals | P2/3 | BB |
| Nivestim | M.D. Anderson Cancer Center | P2 | BB |
| Cytarabine | M.D. Anderson Cancer Center | P3 | BB |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BB |
| Melphalan | Dana-Farber Cancer Institute | P2 | B |
| Enasidenib | Tian Yi Zhang | P3 | B |
+42 more in the Myeloid Leukemia cohort
Other indications for Lispro-Ph20 Component Rhuph20
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hereditary Angioedema | — | P2 | B · 62 |
| Smoldering Plasma Cell Myeloma | — | P3 | B · 59 |
| Melanoma | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lispro-Ph20 Component Rhuph20 in Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lispro-ph20-component-rhuph20-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →